The current treatment status and future of antibody drug conjugates in HER-2-alteration non-small cell lung cancer
10.3760/cma.j.cn112152-20240416-00151
- VernacularTitle:抗体偶联药物在HER-2变异非小细胞肺癌中的治疗现状和未来
- Author:
Yiqi LI
1
;
Kailun FEI
1
;
Zhijie WANG
1
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院内科，北京 100021
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Non-small cell lung cancer;
Human epidermal growth factor receptor 2;
Antibody-drug conjugate;
Precision medicine
- From:
Chinese Journal of Oncology
2025;47(1):86-93
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer(NSCLC) is one of the major histopathological types of lung cancer, accounting for about 85 percent of all lung cancers. The human epidermal growth factor receptor 2 (HER-2) alteration in NSCLC include gene mutations, gene amplifications, and protein overexpression, and is one of the important driving target. Currently, the treatment options for HER-2 altered NSCLC are still relatively limited, and more effective drugs are urgently needed. Antibody-drug conjugates (ADCs) are a highly efficient combination of targeted monoclonal antibodies and cytotoxic drugs that enable precision therapy for tumors. This paper discusses the current status of treating HER-2 variant NSCLC and the research progress of ADCs in HER-2 variant NSCLC, as well as their development prospects in NSCLC.
